Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

95.19EUR
30 Aug 2016
Change (% chg)

-- (--)
Prev Close
€95.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
459,677
52-wk High
€100.35
52-wk Low
€70.68

MRCG.DE

Chart for MRCG.DE

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of... (more)

Overall

Beta: 0.91
Market Cap(Mil.): €12,289.65
Shares Outstanding(Mil.): 129.24
Dividend: 1.05
Yield (%): 1.10

Financials

  MRCG.DE Industry Sector
P/E (TTM): 29.78 36.87 36.61
EPS (TTM): 3.19 -- --
ROI: 5.27 14.68 14.11
ROE: 10.42 15.48 15.03

BRIEF-Moody's changes outlook on Merck KGAA's ratings to stable from negative; affirms ratings

* Moody's changes outlook on Merck KGAA's ratings to stable from negative; affirms ratings

Aug 30 2016

UPDATE 2-Merck KGaA lifts profit forecast on fertility treatment

* Q2 sales of fertility drug Gonal-f jump FX-adjusted 23 pct (Releads, adds details on fertility treatment market, shares)

Aug 04 2016

Merck KGaA lifts FY profit forecast on strong lab supplies

FRANKFURT, Aug 4 German drugs and chemicals maker Merck KGaA on Thursday lifted its full-year earnings outlook after strong growth at its lab supplies business boosted second-quarter results.

Aug 04 2016

BRIEF-Germany's Merck KGaA, AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China

* Merck and Amoy Diagnostics Co Ltd collaborate to bring liquid biopsy RAS biomarker testing to China

Jul 28 2016

CORRECTED-BRIEF-Merck KGaA gets EMA acceptance for review of marketing application

* Merck KGaA, Darmstadt, Germany receives European Medicines Agency (EMA) acceptance for review of marketing authorization application for Cladribine tablets Source text for Eikon: Further company coverage: (Bengaluru Newsroom : +1-646-223-8780)

Jul 18 2016

BRIEF-Merck says EMA accepts cladribine for review marketing authorisation application

* EMA has accepted for review marketing authorization application (MAA) of investigational product cladribine tablets for treatment of relapsing-remitting multiple sclerosis Source text for Eikon: Further company coverage:

Jul 18 2016

REFILE-BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial

* Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer

Jul 07 2016

Pfizer, Germany's Merck begin large ovarian cancer trial

Pfizer Inc and German drugmaker Merck KGaA on Wednesday said they had begun a late-stage trial of their immuno-oncology drug avelumab in combination with standard treatment for ovarian cancer.

Jul 06 2016

BRIEF-Merck KGaA says plans to apply for authorization for Avelumab in H2

* Says plan to apply for marketing authorization for avelumab against merkel cell carcinoma in h2 2016 Further company coverage:

Jun 20 2016

CORRECTED-BRIEF-Merck KGaA, Pfizer present positive mid-stage data on merkel cell carcinoma drug at ASCO

* Say pivotal avelumab study shows positive results in metastatic merkel cell carcinoma

Jun 06 2016

Earnings vs. Estimates